UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.
20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D)
OF THE SECURITIES EXCHANGE
ACT OF 1934
Date of Report (Date of Earliest Event Reported): March 9, 2012
BIOSPECIFICS TECHNOLOGIES
CORP.
(Exact name of registrant as specified in its
charter)
Delaware | 001-34236 | 11-3054851 |
(State or Other Jurisdiction | (Commission File Number) | (I.R.S. Employer |
Of Incorporation) | Identification No.) |
35 Wilbur Street
Lynbrook, NY
11563
(Address of Principal Executive Office) (Zip Code)
516.593.7000
(Registrants telephone number,
including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
INTRODUCTORY COMMENT
Throughout this Current Report on Form 8-K, the terms we, us, our and Company refer to BioSpecifics Technologies Corp.
ITEM 2.02 RESULTS OF OPERATIONS AND FINANCIAL CONDITION
On March 9, 2012, the Company announced its financial and operating results for the fiscal quarter and full year ended December 31, 2011. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K.
In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed to be filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
ITEM 8.01 OTHER EVENTS.
The Company also announced that its Board of Directors has scheduled the Companys Annual Meeting of Stockholders to be held on Friday, June 15, 2012 at 11:00 a.m. EDT, in New York City.
ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS
(d) |
Exhibits | |
99.1 | Press release dated March 9, 2012 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: March 9, 2012 | BIOSPECIFICS TECHNOLOGIES CORP. |
(Registrant) | |
/s/ Thomas L. Wegman | |
Thomas L. Wegman | |
President |
EXHIBIT INDEX
Exhibit No. | Description |
99.1 | Press release dated March 9, 2012 |
BioSpecifics Technologies Corp. Reports Fourth
Quarter
and Full Year 2011 Financial
Results
LYNBROOK, NY March 9, 2012 BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX® in the U.S. and XIAPEX® in Europe and Eurasia, today announced its financial results for the fourth quarter and full year ended December 31, 2011 and provided a corporate update.
We are eagerly awaiting the Peyronies disease Phase III top-line results which are expected late in the second quarter of 2012. We believe there is strong commercial potential for XIAFLEX for this debilitating disease and, if approved, we expect to see an improvement in global sales progress for XIAFLEX, reflected Thomas L. Wegman, President of BioSpecifics. We look forward to initiating our internal human and canine lipoma trials during the first half of 2012, as well as continued revenue growth for XIAFLEX for Dupuytrens contracture and Actelions commercialization in the rest-of-world markets.
Financial Results
BioSpecifics reported net income of $71,326 for the quarter ended December 31, 2011, or $0.01 per basic and diluted share, compared to net income of $140,169, or $0.02 per basic and diluted common share for the same period in 2010. For the full year ended December 31, 2011, the Company reported net income of $6.6 million, or $1.04 per share on a basic and $0.95 on a fully diluted basis, compared to a net loss of $1.5 million, or $0.24 per share on a basic and fully diluted basis in the same period in 2010.
Total revenue for the fourth quarter of 2011 was $2.6 million, compared to $1.1 million for the same period in 2010. For the full year ended December 31, 2011, total revenue was $11.4 million, compared to $5.7 million in 2010. Total royalty, mark-up on cost of goods sold and earn-out revenues for the year ended December 31, 2011 increased to $6.3 million due to higher net sales of XIAFLEX and Santyl® reported to BioSpecifics by its partners Auxilium Pharmaceuticals, Inc. (Auxilium) and DFB Biotech, Inc. (DFB) and their affiliates as compared to $2.3 million in the same period in 2010.
1
Total licensing fees consisting of licensing and sublicensing fees and milestones were $5.0 million compared to $3.0 million in the 2010 period. Licensing fees recognized from Auxilium for the full year 2011 were $0.4 million, compared to $0.8 million for the same period in 2010. These licensing revenues related to cash payments received in prior years and amortized over the expected development period. Sublicensing fees recognized in 2011 were $0.75 million compared to zero in the same period in 2010. BioSpecifics recognized $0.75 million of the $15.0 million paid to Auxilium by Asahi Kasei Pharma Corporation (Asahi) for the rights to commercialize XIAFLEX for the treatment of Dupuytren's contracture and Peyronie's disease in Japan. Milestone revenue recognized for the year ended December 31, 2011 was $3.825 million compared to $2.275 million in the 2010 period. In the 2011 period, the Company recognized three milestones related to the first sale of XIAFLEX in the United Kingdom, Germany and Spain by Pfizer, Inc. (Pfizer) for Dupuytrens contracture. In the 2010 period, BioSpecifics recognized two milestone payments of which $1.275 million was related to the scientific/technical review procedure of Pfizers Marketing Authorization Application for XIAFLEX for Dupuytrens contracture in Europe and $1.0 million was related to the approval of XIAFLEX for Dupuytrens contracture by the FDA in February 2010.
Consulting revenues recognized for the periods ended December 31, 2011 and 2010 were $46,667 and $0.3 million, respectively. The change in consulting and technical assistance obligations under the DFB Agreement is due to the expiration of the consulting services in March 2011.
Research and development expenses for the fourth quarter of 2011 were $0.3 million, compared to a credit of $34,256 for the same period in 2010. This increase in research and development expenses was due to clinical development activities and research and development consulting expenses. The credit in the 2010 period in research and development was mainly due to an adjustment during the quarter to the amount of third party lyophilization expenses reported to BioSpecifics by Auxilium. For the year ended December 31, 2011, research and development expenses were $1.0 million, compared to $1.2 million in 2010. This decrease in research and development expenses was primarily due to lower third party development costs that are reimbursable under the Auxilium Agreement partially offset by increased clinical development expenses.
General and administrative expenses for the fourth quarter of 2011 were $1.1 million, compared to $1.5 million for the same period in 2010. For the year ended December 31, 2011, general and administrative expenses were $5.2 million, compared to $6.5 million in 2010. The decrease in general and administrative expenses was due to lower stock based compensation, consulting services, general legal fees and services related to investor relations partially offset by increases in patent costs and director fees.
2
As of December 31, 2011, BioSpecifics had cash and cash equivalents and investments of $8.2 million, compared to $7.8 million on December 31, 2010.
Recent Corporate Highlights:
Upcoming Anticipated Milestones:
3
Upcoming Annual Meeting:
Webcast and Conference Call
The Company will host a conference call today at 8:30 a.m. EST to discuss these fourth quarter and full year 2011 results.
4
In order to participate in the conference call, please dial 1-800-860-2442 (domestic) or 1-412-858-4600 (international). The live webcast can be accessed under Calendar of Events in the Investor Relations section of the Companys website at www.biospecifics.com, or you may use the link: http://www.videonewswire.com/event.asp?id=85437.
A replay of the call will be available one hour after the end of the conference on March 9, 2012 until 9:00 a.m. EDT on March 26, 2012. To access the replay, please dial 1-877-344-7529 (domestic) or 1-412-317-0088 (international) and reference the access code 10010771. The archived webcast will be available for 90 days in the Investor Relations section of BioSpecifics website at www.biospecifics.com.
About BioSpecifics Technologies Corp.
BioSpecifics Technologies Corp. is a biopharmaceutical company that has developed injectable collagenase for twelve clinical indications. Its partner Auxilium Pharmaceuticals, Inc. markets XIAFLEX® in the U.S. for the treatment of Dupuytren's contracture in adults with a palpable cord in the palm and is also developing XIAFLEX for the treatment of Peyronie's disease, which is currently in Phase III pivotal clinical trials, as well as for Frozen Shoulder (Adhesive Capsulitis) and cellulite which are in Phase II and Phase I respectively. Pfizer, Inc. is responsible for marketing XIAPEX® for Dupuytren's contracture in the 27 European Union member countries and 19 other European and Eurasian countries and also has commercialization and development rights for Peyronie's disease in these same territories. Asahi Kasei Pharma Corporation has development and commercial rights for XIAFLEX for Dupuytren's contracture and Peyronie's disease in Japan and Actelion Pharmaceuticals has the development, supply and commercialization rights in Canada, Australia, Brazil and Mexico. BioSpecifics is developing XIAFLEX internally for human and canine lipomas. More information about the Company may be found on its website at www.biospecifics.com.
5
Forward-Looking Statements
This release contains forward-looking statements within the meaning of, and made pursuant to the safe harbor provisions of, the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact, including statements regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, expected revenue growth, and the assumptions underlying or relating to such statements, are forward-looking statements. In some cases, you can identify these statements by forward-looking words such as believe, expect, anticipate, plan, estimate, likely, may, will, could, continue, project, predict, goal, the negative or plural of these words, and other similar expressions. Our forward-looking statements are my predictions based on our current expectations and our projections about future events. These are a number of important factors could cause our actual results to differ materially from those indicated by such forward-looking statements, including the statements made by us or by our partner Auxilium Pharmaceuticals, Inc. (Auxilium) regarding progress toward achievement of Auxiliums objectives for the sale and marketing of XIAFLEX® for Dupuytrens contracture in the U.S., including, among other things, developments in the reimbursement process; the ability of Pfizer, Inc. to achieve its objectives for XIAPEX® in Europe; the ability of Asahi Kasei Pharma Corporation to achieve its objectives for XIAFLEX in Japan; the ability of Actelion Pharmaceuticals Ltd. to achieve its objectives for XIAFLEX in Canada, Australia, Brazil and Mexico; the success of the Phase III trials for XIAFLEX for the treatment of Peyronies disease; the potential market for XIAFLEX in a given indication; the initiation and outcome of clinical trials for additional indications including frozen shoulder, cellulite, human lipoma and canine lipoma, all of which will determine the amount of milestone, royalty and sublicense income we may receive; the potential of XIAFLEX to be used in additional indications; the timing of results of any clinical trials; the receipt of any applicable milestone payments from Auxilium; whether royalty payments we are entitled to receive will exceed set-offs; and other risk factors set forth in our Form 10-K for the year ended December 31, 2010, Form 10-Q for the quarter ended September 30, 2011 and our reports on Form 8-K filed with the SEC. All forward-looking statements included in this release are made as of the date hereof, and we assume no obligation to update these forward-looking statements.
Contact:
BioSpecifics Technologies Corp.
Thomas L. Wegman, President
(516) 593-7000
thomas_wegman@biospecifics.com
6
BioSpecifics Technologies Corp.
Consolidated Statements
of Operations
Three months ended | Twelve months ended | |||||||||||
December 31 | December 31 | |||||||||||
2011 | 2010 | 2011 | 2010 | |||||||||
Revenues: | (Unaudited) | (Audited) | ||||||||||
Net sales | $ | 8,541 | $ | 2,180 | $ | 21,998 | $ | 34,508 | ||||
Royalties | 1,853,276 | 961,956 | 6,314,959 | 2,320,729 | ||||||||
Licensing revenue | 746,775 | 109,276 | 5,012,102 | 3,026,111 | ||||||||
Consulting fees | - | 70,000 | 46,667 | 280,000 | ||||||||
Total Revenues | 2,608,592 | 1,143,412 | 11,395,726 | 5,661,348 | ||||||||
Costs and expenses: | ||||||||||||
Research and development | 265,063 | (34,256 | ) | 972,078 | 1,223,931 | |||||||
General and administrative | 1,059,194 | 1,500,796 | 5,231,881 | 6,470,449 | ||||||||
Total costs and expenses | 1,324,257 | 1,466,540 | 6,203,959 | 7,694,380 | ||||||||
Operating income (loss) | 1,284,335 | (323,128 | ) | 5,191,767 | (2,033,032 | ) | ||||||
Other income (expense): | ||||||||||||
Interest Income | 14,719 | 17,048 | 55,780 | 86,310 | ||||||||
Other, net | 1,344 | 13,130 | 15,823 | 13,130 | ||||||||
Qualifying Therapeutic Discovery Grant | - | 426,403 | - | 426,403 | ||||||||
16,063 | 456,581 | 71,603 | 525,843 | |||||||||
Income (loss) before income tax | 1,300,398 | 133,453 | 5,263,370 | (1,507,189 | ) | |||||||
Income tax benefit (expense) | (1,229,072 | ) | 6,716 | 1,338,256 | (1,351 | ) | ||||||
Net income (loss) | $ | 71,326 | $ | 140,169 | $ | 6,601,626 | $ | (1,508,540 | ) | |||
Basic net income (loss) per share | $ | 0.01 | $ | 0.02 | $ | 1.04 | $ | (0.24 | ) | |||
Diluted net income (loss) per share | $ | 0.01 | $ | 0.02 | $ | 0.95 | $ | (0.24 | ) | |||
Shares used in computation of
basic net income (loss) per share |
6,350,770 | 6,280,268 | 6,340,648 | 6,261,214 | ||||||||
Shares used in computation of
diluted net income (loss) per share |
6,868,087 | 7,182,558 | 6,952,386 | 6,261,214 |
BioSpecifics Technologies Corp.
Selected Consolidated
Balance Sheet Data
(Unaudited)
December 31 | ||||||
2011 | 2010 | |||||
Cash and cash equivalents | $ | 3,196,831 | $ | 2,470,852 | ||
Short term investments | 5,000,000 | 5,360,970 | ||||
Accounts and income tax receivable, net | 3,481,637 | 2,171,511 | ||||
Deferred tax assets | 3,047,955 | - | ||||
Working capital | 11,970,264 | 5,990,899 | ||||
Total assets | 16,265,073 | 11,518,701 | ||||
Long-term liabilities | 276,520 | 713,619 | ||||
Total stockholders' equity | 14,872,314 | 6,700,723 |
7